GSK nets a deal with Cana­di­an gov­ern­ment for flu vac­cine man­u­fac­tur­ing

While Covid-19 and mon­key­pox man­u­fac­tur­ers are get­ting more con­tracts, the Cana­di­an gov­ern­ment is still con­cerned with the flu, es­pe­cial­ly as its sea­son will soon be up­on North Amer­i­ca in a few months.

Last Fri­day, GSK an­nounced an agree­ment with the Cana­di­an gov­ern­ment to man­u­fac­ture pan­dem­ic and sea­son­al in­fluen­za vac­cines.

The four-year agree­ment, which ex­tends through March 2026, in­cludes GSK sup­ply­ing as many as 80 mil­lion dos­es of Arepan­rix, an ad­ju­vant­ed pan­dem­ic flu vac­cine, in case there is an in­fluen­za pan­dem­ic. The deal will al­so have GSK pro­duce a min­i­mum of 4 mil­lion dos­es per year of the sea­son­al flu vac­cine Flulaval Tetra. Both vac­cines will be man­u­fac­tured at its 230,000-square-foot fa­cil­i­ty in Sainte-Foy, Que­bec.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER